

## Special Issue

# Antibody against Viral Infection: Advances in the Era of Therapeutic Monoclonal Antibody

### Message from the Guest Editor

Antibodies are one of the key components of the immune system to control viral infections. The control by this armed component of the humoral immunity is dual, based on direct interference with the viral replication process (mainly through a neutralization effect on virions) or by targeting infected cells to immune effector cells. The recent advent of the era of monoclonal antibodies, made possible by hybridoma technology, has opened new avenues in the field of therapeutics for viral disease.

This Special Issue of *Vaccines* is open to original reports, perspectives, reviews, or research articles focusing on recent advances on the use of antibodies against viral infection. The submission of articles covering the following research areas is especially encouraged:

- Experimental development, characterization, or clinical evaluation of novel or existing antiviral antibodies;
- Mechanisms of antiviral activities of antibodies;
- Development of vaccine strategies to elicit antiviral antibodies.

### Guest Editor

Dr. Laurent Dacheux

Institut Pasteur, National Reference Centre for Rabies, WHO Collaborating Center for Reference and Research on Rabies, Lyssavirus Epidemiology and Neuropathology Unit, 75724 Paris, France

### Deadline for manuscript submissions

closed (31 July 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/44325](https://mdpi.com/si/44325)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).